Screening for human immunodeficiency virus type 1 and 2 in a Turkish blood donor population
Altuglu, I.; Sayiner, A.A.; Erensoy, S.; Zeytinoglu, A.; Bilgiç, A.
International Journal of Infectious Diseases Ijid Official Publication of the International Society for Infectious Diseases 2(4): 202-204
1998
ISSN/ISBN: 1201-9712 PMID: 9763502 DOI: 10.1016/s1201-9712(98)90053-4Document Number: 532897
To determine the prevalence of human immunodeficiency virus-1 and -2 infection in voluntary blood donors at a university hospital in the third largest city of Turkey and to evaluate the HIV testing strategy for notifying blood donors. Between July 1995 and August 1997, 36,373 voluntary blood donors who met the criteria for donating blood were tested for the presence of HIV-1 and -2 antibodies by using an automated enzyme-linked fluorescent immunoassay. Repeatedly reactive samples were subjected to a different enzyme-linked immunosorbent assay (ELISA) and a line immunoassay (LIA) for the detection of antibodies. Of the 36,373 samples tested 72 were found to be repeatedly reactive or borderline by the first screening enzyme immunoassay (EIA). None of the 72 samples was reactive by the second EIA. These samples were further tested by LIA: 64 were negative on the line immunoassay and 8 were indeterminate. Three of eight donors who had indeterminate results by LIA were tested for HIV-1 DNA by polymerase chain reaction (PCR) and were found to be negative. One additional donor with an indeterminate LIA was found to be negative by EIA and LIA during the 6-month follow-up period. Donor questioning, repeat EIA testing, LIA testing, and HIV-1 DNA analysis did not confirm evidence for HIV infection among this blood donor population. Blood donor notification of test results according to the World Health Organization (WHO) strategy III was found to be an appropriate approach.